Physician profile
Umar Sheikh
NPI 1558981274
$10,454.27
in general payments reported to CMS, 2019-2025
28 companies · $3,701 in 2025
The $3,701 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $591 · 2022: $2,232 · 2023: $1,972 · 2024: $1,957 · 2025: $3,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,880 · Travel and Lodging: $1,652 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,879.76 |
| Travel and Lodging | $1,652.03 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,226.10 | 2022-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $659.45 | 2021-2025 | Ilumya |
| Genzyme Corporation | $644.00 | 2021-2025 | |
| Pfizer INC. | $445.86 | 2022-2025 | |
| Incyte Corporation | $430.05 | 2022-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $397.79 | 2022-2024 | Tremfya |
| Janssen Biotech, INC. | $393.64 | 2024-2025 | Tremfya |
| Ucb, INC. | $383.90 | 2021-2025 | Cimzia, Bimzelx |
| Regeneron Healthcare Solutions, INC. | $382.84 | 2022-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $329.56 | 2022-2025 | Nemluvio |
| Vyne Pharmaceuticals INC. | $264.55 | 2021 | |
| Dermavant Sciences, INC. | $231.83 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $225.72 | 2025 | |
| Novartis Pharmaceuticals Corporation | $208.75 | 2025 | |
| Lilly USA, LLC | $205.55 | 2023-2025 | Ebglyss, Taltz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $190.26 | 2022-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $157.44 | 2023-2025 | Sotyktu |
| Kyowa Kirin, INC. | $132.61 | 2022 | |
| Lnhc, INC | $125.00 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.41 | 2024 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Arcutis Biotherapeutics, INC. | $59.36 | 2025 | Zoryve |
| Botanix Sb INC | $50.16 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.21 | 2025 | Jublia, Cabtreo |
| Organon LLC | $32.53 | 2025 | Vtama |
| Amgen INC. | $25.83 | 2025 | Otezla |
| Cipher Pharmaceuticals US LLC | $16.33 | 2025 | Natroba, Spinosad |
| Strata Skin Sciences, INC. | $13.55 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umar Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.